ESR1 and breast cancer: Triple‐negative breast cancer (TNBC) accounts for approximately 15%–20% of all breast cancers and is defined as a lack of the expression of estrogen receptor (ER), progesterone receptor (PgR), and the amplification of the human epidermal growth factor 2 (HER2) receptor [1].